<DOC>
	<DOC>NCT01674621</DOC>
	<brief_summary>To determine the clinical safety and efficacy of BA058 Transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when compared to Transdermal Placebo and BA058 Injection for 6 months of treatment.</brief_summary>
	<brief_title>Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<criteria>Postmenopausal woman, less than 85 years old. BMD Tscore ≤ 2.5 of spine or hip (femoral neck) or ≤ 2.0 with previous fracture (within 5 years). Normal physical exam, vital signs, electrocardiogram (ECG) and medical history. Laboratory tests within the normal range including serum calcium, Vit D, PTH(184), serum phosphorus and alkaline phosphatase. BMD Tscore ≤ 5.0 at the lumbar spine or hip. History of bone disorders (e.g., Paget's disease) other than postmenopausal osteoporosis. Significantly impaired renal function. History of any cancer.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>BA058</keyword>
	<keyword>Abaloparatide-SC</keyword>
	<keyword>abaloparatide</keyword>
	<keyword>Abaloparatide-TD</keyword>
	<keyword>Osteo</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Transdermal</keyword>
	<keyword>Patch</keyword>
</DOC>